Concord manufactures over 30 products across therapy segments such as immunosuppressant, oncology, antifungal, and antibacterial. Shares of Concord Biotech Ltd ended at ₹1,438, down by ₹4.80, or 0.33%, on the BSE.
Shares of recently listed Concord Biotech Ltd are in focus today after Norges Bank bought nearly nine lakh shares or 0.9% stake in the firm in bulk deals. Norges Bank is the central bank of Norway. The deal was carried out on account of the government pension fund global. The transaction was done at Rs 900.05 per share. The total value was Rs 80.91 crore with 8,99,037 shares changing hands in the deal.
Concord Biotech Share Price: Find the latest news on Concord Biotech Stock Price. Get all the information on Concord Biotech with historic price charts for NSE / BSE. Experts & Broker view also get the Concord Biotech Ltd. buy/sell tips detailed news, announcements, Forecasts, Analysts, Valuation, Earning forecasts, Estimates, Recommendations, Analysts Ratings, financial report, company information, annual report, balance sheet, profit & loss account, results and more.
India Business News: India's Concord Biotech saw a 24.6% surge in its share prices to Rs 923 on Friday. With the biopharma company's IPO initially priced at Rs 741 rupees,
Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022. The company is backed by Rakesh Jhunjhunwala s Rare Enterprises and another leading investment firm Quadria Capital Fund. Ahead of the listing, the company s shares commanded a premium of Rs 120 in the unlisted market.